79 results
8-K
EX-99.1
ODYY
Odyssey Health, Inc.
13 Dec 23
Regulation FD Disclosure
5:10pm
of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only
8-K
kvxvz1mo 0ta
5 Oct 23
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
6:30am
8-K
EX-2.1
q1ms v1uh7gpzxt5t5
5 Oct 23
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
6:30am
8-K
EX-99.1
l3lkhz6cckvh
5 Oct 23
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
6:30am
8-K
EX-10.1
pd8qu 1yaq2r1
18 Aug 23
Entry into a Material Definitive Agreement
5:10pm
8-K
EX-99.1
yx3c104w
25 Nov 22
Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development
8:30am
8-K
EX-10.1
p7o1 p355
23 Nov 22
Entry into a Material Definitive Agreement
5:10pm
8-K
EX-99.1
lim r9iziqu6el
4 Nov 22
Odyssey Health Inc. Strengthens Commitment to Odyssey NeuroPharma Through Expansion of Executive Team
4:16pm
8-K
EX-10.1
c38pcqbu do16rdf
4 Nov 22
Odyssey Health Inc. Strengthens Commitment to Odyssey NeuroPharma Through Expansion of Executive Team
4:16pm
8-K
EX-10.2
x4sjl9hed6d
4 Nov 22
Odyssey Health Inc. Strengthens Commitment to Odyssey NeuroPharma Through Expansion of Executive Team
4:16pm
8-K
EX-99.1
mv8kl8qzpr150urn8dh
1 Nov 22
Odyssey Health Inc. Files Full US Patent Application on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device
8:45am
8-K
EX-99.1
jbfeobjx
30 Sep 22
Odyssey Health, Inc. Makes Statement Regarding its Concussion Drug Development Program
5:51pm
8-K
EX-99.1
fwre153i
30 Sep 22
Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug
5:20pm
8-K
EX-99.1
8qcu4xbuxhxoilb8a9ac
18 Aug 22
Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial
4:02pm